A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994. identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously.
INTRODUCTION

Lamotrigine
(LTG) and vigabatrin (GVG) are increasingly being prescribed to treat children with severe epilepsy. Assessment of the clinical efficacy and safety of new antiepileptic drugs (AED), such as LTG and GVG in children using controlled clinical trials poses special problems' and, to date, has provided limited useful information for application of use of these drugs in clinical, everyday, paediatric practice'. The aim of the present study was to characterize the relative efficacy and tolerability of two new AEDs, LTG and GVG, in the every-day, clinical practice of treating children with severe epilepsy, refractory to conventional therapy.
PATIENTS AND METHODS
A survey of LTG and GVG treatment was undertaken between September 1994 and February 1995 at the 1059-l 31 l/97/060479 + 05 $12.00/O University of Wales College of Medicine, based on the case notes of patients treated by one of the authors, a consultant paediatric neurologist, working in a tertiary referral outpatient clinic at the University Hospital of Wales, Heath Park, Cardiff, in the UK. A cohort of 109 children, prescribed LTG and GVG between 1987 and 1994 , was identified from patients seen for management of epilepsy over a period of 7 years. Three hundred children are seen annually, but many individuals attended for most of the 7 years under review. It should be noted that this paediatric neurology clinic serves a population of two million in the south-west of Britain, including South Wales and south-west England. The identification of patients prescribed LTG was comprehensive and the GVG subset comprised approximately 90% of the total population prescribed this drug.
A pro forma, slightly modified from that previously designed for use in a similar study of these two drugs in an adult population treated in Liverpoo13, was used to define demography, duration of therapy, dosage and concomitant AED therapy, adverse (6-O effects leading to discontinuation, epilepsy and seizure type and aetiology, pre-existing or associated neurological, intellectual and behavioural dysfunction and response of seizure control to treatment with LTG and/or GVG. Seizure control was evaluated by estimating the average, monthly seizure frequency over 3 months before the introduction of LTG or GVG and for the last 3 months of treatment with the maximal dose of the new drug. Data were initially obtained from hospital case notes, missing information being obtained from general practitioners, paediatricians and families, when necessary. The completed data record forms were checked, collated and entered onto a computerized database for further analysis, using summary statistics and the construction of a Kaplan-Meier survival curve. The Kaplan-Meier curves for LTG and GVG apply only to treatment with each of these two index drugs. 
RESULTS
and 80 of the 86 patient treatments (93%) with GVG, had severe epilepsy, defined as more than one major seizure per month or more than one minor seizure per week. Patients were taking an average of two other AEDs when they commenced LTG or GVG and the majority had significant, pre-existing disorders, as outlined in Table 1 . The database was derived from a total population of 300 patients treated annually for severe refractory epilepsy in a tertiary referral centre. A subset of 109 children was identified from the clinic's database, who had been treated with add-on LTG and/or GVG. There were 79 patient treatments with LTG and 86 with GVG. There were 42 patients who were treated with add-on LTG, 52 who were treated with add-on GVG and 20 who were treated with both drugs simultaneously. Fifteen patients were treated with both drugs serially, 12 ending up on LTG and three continuing to take GVG at the time of audit.
The demographic data are shown in Table 1 . The age and gender distribution and pattern of associated cerebral dysfunction were similar for the population subset treated with LTG and GVG. Almost all patients, 78 of the 79 patient treatments (99%) with LTG It was estimated from the Kaplan-Meier curve that 71 and 62% of patients would be expected to continue taking LTG or GVG, respectively after 40 months (Fig. 1) . Improvement in seizure control by 50% or more, at the time of the audit, was seen in 65% of LTG patient treatments and in 58% of GVG patient treatments, for all epilepsy syndromes (Fig. 2) . There was similar improvement in seizure control, associated with treatment with both drugs, in patients with localization-related epilepsy syndromes, but there was a higher proportion of patients with generalized epilepsy improved by LTG, compared with that improved by GVG (Fig. 2) . There was also a higher percentage of patient treatments with LTG (16%), compared with those with GVG (lo%), in which patients became seizure free (Fig. 3) . It can be seen from this figure that only patients on LTG The present survey of the initially add-on use of two new AEDs, LTG and GVG, in a relatively large tertiary referral outpatient population of children with severe epilepsy was retrospective and nonrandomized, as was the survey previously carried out on both these drugs in adults3. A number of potential systematic biases may have influenced the results and conclusions, including patient selection biases, such as the earlier introduction of GVG, resulting in the use of LTG in a more therapeutically refractory patient population and the apparent early avoidance of the use of GVG in patients with generalized epilepsy syndromes. Furthermore, adverse event recording was unblinded in the present retrospective study, as in the previous study, thereby introducing a further potential bias in attributing unwanted effects to LTG or GVG. This study was comprehensive, as far as the inclusion of all patients taking LTG, and included approximately 90% of all patients taking GVG. The retention times for both drugs were of reasonable duration, consistent with informative patterns of responsiveness and adverse events. The survey was that of a refractory paediatric population with severe epilepsy, as demonstrated by the pre-treatment seizure frequency, the relatively high incidence of associated neurological and intellectual impairment and by the concomitant intake of at least two other AEDs when the patients were started on LTG or GVG.
The present study suggests that LTG is as effective as GVG for the control or partial seizures in children and supports a different spectrum of efficacy for LTG and GVG, suggesting that LTG is a broadspectrum agent, effective for both localization-related and generalized epilepsy syndromes, whereas GVG with generalized epilepsy became seizure free and that there was a higher proportion of patients on GVG with localization-related epilepsy, who became seizure free (Fig. 3) . Patient accountability, with respect to continuation of LTG or GVG and the reasons for discontinuing the audited drug, are shown in Table 2 , from which it is evident that similar proportions of patients discontinued both drugs due to an adverse experience (Table 3) but there was a higher proportion of patients who discontinued GVG, compared with LTG, due to lack of efficacy. The seizure response of patients with special paediatric epilepsy syndromes is shown in Table 4 . The therapeutic response of patients with Lennox-Gastaut syndrome to LTG and GVG and of patients with myoclonic-astatic epilepsy and with epilepsy with myoclonic absences is worth noting. Table 5 indicates the relevant LTG and GVG daily dose ranges. The mean plasma LTG level of patients who responded with a 50% or more decrease in seizure frequency was 26.5 pmol/l (6.6 mg/l), with a 95% confidence interval of O-53 pmol/l (O-13 mg/l), compared with non-responders, in whom the mean plasma LTG level was 18.4 pmol/l (4.6 mg/l), with a 95% confidence interval of -541 pmol/l (-l-10 mg/l). There was a trend for the plasma LTG concentration to be related to maximal daily dose, expressed as mglkglday, in patients who did not take concomitant sodium valproate (VPA). The value for the correlation between the plasma LTG level and dose factored for weight, in the 51 patients in whom it was measured, was 2.3164 (r2 = 5.3657). Visual plotting of plasma LTG level vs. dose, factored for weight, demonstrated a better correlation for patients not receiving VPA (r = 5.3645, r2 = 28.7779, n = 28) than for the total group, including those on VPA (r = 2.3164, r* = 5.3657). There was no obvious correlation between the plasma LTG concentration and seizure control, or between the plasma LTG concentration and the number of patients discontinued because of adverse experiences. should be selectively prescribed for .children with localization-related epilepsy, characterized by partial seizures. This phenomenon may have been reflected by the higher withdrawal rate of GVG compared with that of LTG, because of the lack of efficacy of GVG in children with generalized epilepsy syndromes. The pattern of therapeutic efficacy for LTG and GVG in children with specific epilepsy syndromes is of note. Both drugs appeared to provide reasonable therapeutic response in children with the Lennox-Gastaut syndrome and epilepsy syndromes associated with tuberous sclerosis, while LTG appeared to be particularly effective for treating myoclonic-astatic epilepsy, epilepsy with myoclonic absences, severe myoclonic epilepsy of infancy and benign epilepsy of childhood with centro-temporal spikes 'plus'. LTG was also effective in treating one child with Batten's late infantile syndrome and one with absence epilepsy of childhood, while GVG, as expected, was associated with a 50% or greater seizure decrease in two children with mesial temporal sclerosis, two children with intra-cerebral tumours and one child with neurofibromatosis Type 1. The overall prevalence of adverse experiences, resulting in discontinuation of LTG and GVG, was similar for both drugs. However, the type of adverse experience leading to withdrawal was characterized by a drug hypersensitivity skin rash and seizure aggravation in children treated with LTG, compared with aggressive behaviour and, to a lesser extent, seizure aggravation in children treated with GVG. Overall, both new AEDs were well tolerated.
The plasma LTG concentration was measured at maximal dose in two-thirds of children treated with of lamotrigine and vigabatrin treatment in children this drug. There was a trend for the plasma LTG concentration to be related to maximal daily dose, in the absence of concomitant VPA therapy, However, there was no apparent relationship between plasma LTG concentration and either seizure control or discontinuation because of adverse experiences. This study is not a substitute for randomized, controlled trials of LTG and GVG, but it does reflect the relative clinical effectiveness of these two AEDs in the real world of the treatment of children with severe epilepsy, refractory to previous treatment with conventional AEDs, as did a previous survey in adults3. Trials of new AEDs in children have been delayed until data about the drugs were available in adults'. Thus there have been relatively few controlled trials of LTG and GVG in children with severe epilepsy, to date. A clinical overview of data from five almost identical protocols provided information about the results of treatment with LTG in 285 children with refractory epilepsy4. The report was related to three studies of LTG in children, including a single-blind study, a pharmacokinetic study and the study of a group receiving compassionate therapy. All the children, whose results were reviewed, received LTG as open, add-on therapy, with similar results and conclusions, compared with those found in the present study which, however, found a higher efficacy for seizure reduction with LTG, particularly for patients with localization-related epilepsy syndromes. It should be noted that this review4 included results of children assessed after the first 12 weeks of maintenance dosage. In a recently published evaluation of LTG treatment of childhood epilepsies, pooled data from five open, add-on studies indicated that it was efficacious in patients with a broad range of seizure types, especially absence seizures and atonic seizures, and that it was well tolerated5.
Similarly, there are relatively sparse data related to the therapeutic, cost/effective ratio of GVG for the treatment of children with epilepsy syndromes, refractory to conventional AED therapy2v6-*. There are a limited number of reports, comprising uncontrolled observations on children with localization-483 related syndromes and those with special epilepsy syndromes, such as Lennox-Gastaut syndromeg, West syndrome and epilepsy syndromes associated with tuberous sclerosis** lo* ' ' , treated as part of open, uncontrollable therapeutic trials with GVG. The present retrospective survey of children with epilepsy syndromes refractory to conventional AEDs, chronically treated with LTG and GVG, thus serves to generate hypotheses concerning the more rational use of these two drugs, which can subsequently be tested by prospective, controlled trials.
